InvestorsHub Logo
Followers 4
Posts 549
Boards Moderated 0
Alias Born 04/11/2017

Re: None

Wednesday, 11/22/2017 9:59:03 AM

Wednesday, November 22, 2017 9:59:03 AM

Post# of 74446
First, I am very high on VDRM, but I think the major value is down the road in 2018 with their other products. As I read it, and maybe I am wrong, Biogenx is the primary distributor of Vitastem. According to VDRM disclosure, the licensing deal isn't that great with Biogenx. My Biogenx calculation
15,000 units x $79 = $1,185,000. Less cost of mkt, distribution, production (assume 35%) = $770,250. But, VDRM only gets 5%. Total monthly VDRM revenue based on 15,000 units sold from Biogenx = $38,512.
We need other distributors with better terms, and they already have one in South Africa on awesome terms. Regardless, this company is going to boom imo. Future pipeline is huge. I am only stating what I see. Honestly, I hope I am wrong.

Copy below:

On January 1, 2017, the Company entered into a licensing and distribution agreement with Biogenx, Inc. for
the purpose of commercializing and distributing a topical antibiotic product to be branded VitaStem. The product
will carry the Company’s tetracycline-based technology. This product will be separately registered with the FDA.
Pursuant to the agreement, the Company will receive 5% of the gross profit from VitaStem sales. For purposes of
the agreement, gross profit is defined as total revenues less cost of production, distribution and marketing. The
agreement will terminate on December 31, 2022 unless extended by both parties. Biogenx, Inc. has the right to
terminate the agreement early with two month notice if it deems the arrangement to not be financially viable.
On January 1, 2017, the Company entered into a licensing and distribution agreement with Vage Nigeria,
Ltd. for the purpose of commercializing and distributing a topical antibiotic product to be branded Dermafix. The
product will carry the Company’s tetracycline-based technology. This product will be separately registered with the
FDA. Pursuant to the agreement, the Company will receive 50% of the net sales from Dermafix. For purposes of the
agreement, net sales is defined as total revenues less cost of production, distribution and marketing (which includes
taxes, discounts, allowances, credits for returns, rebates, import duties and other governmental charges, freight and
transportation). The agreement will terminate on December 31, 2022 unless extended by both parties. Vage Nigeria,
Ltd. has the right to terminate the agreement early with two month notice if it deems the arrangement to not be
financially viable.